Shrestha Rajeev, Ghale Anish, Chapagain Bijay Raj, Gyawali Mahasagar, Acharya Trishna
Department of Pharmacy, Janamaitri Foundation Institute of Health Sciences, Tribhuvan University, Lalitpur, Nepal.
Nepal Health Research Council, Kathmandu, Nepal.
SAGE Open Med. 2017 Nov 17;5:2050312117738691. doi: 10.1177/2050312117738691. eCollection 2017.
The access to essential medicines for non-communicable disease treatment is unacceptably low worldwide. The fundamental right to health cannot be fulfilled without equitable access to essential medicines.
A cross-sectional study was carried out in 94 community pharmacies of Kathmandu valley. Non-probability quota sampling method was adopted for the purpose. Village Development Committees with more than 5000 populations were included in the study. The availability of the selected essential medicines, their price and producer identity were observed. Data entry and analysis were carried out in Microsoft Excel and Statistical package for social science.
The availability of the essential medicines was not 100% in Kathmandu valley. High competition and high price variation were seen in metformin 500 mg (254.6%) and atorvastatin 10 mg (327.6%). The study showed that maximum (54.7%) brands were manufactured in Nepal. Furthermore, atorvastatin 10 mg (0.6 day wage) was found to be quite expensive, and glibenclamide 5 mg (0.1 day wage) was the cheapest one for diabetes mellitus treatment for 1 month of treatment period compared to daily wages of other essential medicines.
The availability of the selected essential medicines was found to be ununiform and insufficient in the entire region. High competition was observed in the products with high price variation, and the access to cost-effective brand was poor. Furthermore, it was found that government salary is affordable to treat non-communicable disease with the help of the essential medicines.
在全球范围内,用于治疗非传染性疾病的基本药物的可及性低得令人无法接受。如果不能公平获取基本药物,健康的基本权利就无法实现。
在加德满都谷地的94家社区药房开展了一项横断面研究。为此采用了非概率配额抽样方法。研究纳入了人口超过5000的乡村发展委员会。观察所选基本药物的可及性、价格和生产商信息。数据录入和分析在Microsoft Excel和社会科学统计软件包中进行。
加德满都谷地的基本药物可及性并非100%。二甲双胍500毫克(254.6%)和阿托伐他汀10毫克(327.6%)存在高度竞争且价格差异很大。研究表明,最大比例(54.7%)的品牌是在尼泊尔生产的。此外,与其他基本药物的日工资相比,阿托伐他汀10毫克(0.6日工资)被发现相当昂贵,而格列本脲5毫克(0.1日工资)是治疗1个月糖尿病最便宜的药物。
在所研究的整个地区,所选基本药物的可及性不均衡且不足。在价格差异大的产品中观察到高度竞争,且获取性价比高的品牌的机会较差。此外,研究发现,借助基本药物,政府工资足以用于治疗非传染性疾病。